Genomics launches predictive Health Insights test in UK
Oxford-based Genomics has announced the nationwide launch of its Health Insights predictive clinical tool across Great Britain, marking the first UKCA-marked and MHRA registered test that combines genetic and clinical factors to predict and prevent common diseases. The announcement was made at HLTH Europe 2025 in Amsterdam on 17 June 2025.
Sir Peter Donnelly, Co-Founder and CEO of Genomics.
The Health Insights UK test provides healthcare professionals with polygenic risk scores (PRS) for cardiovascular disease, type 2 diabetes, breast cancer, and prostate cancer, using sophisticated algorithms that analyse millions of DNA variants to assess genetic susceptibility to disease.
Regulatory approval and clinical validation
The test represents a significant regulatory milestone as the first product of its kind to receive both UKCA marking and MHRA registration in the UK. The development followed Genomics’ successful trial of an investigational cardiovascular risk tool in the NHS in 2021, which demonstrated robust clinical acceptance and utility in primary care settings.
“Doctors can now provide more personalised, more preventative, and better informed advice to their patients, and get them into the appropriate prevention, screening, and treatment pathways earlier,” said Professor Sir Peter Donnelly, co-founder and CEO of Genomics. “This product ushers in a new era of truly personalised, preventative healthcare.”
Clinical implementation and provider network
Health Insights is now available nationwide across Great Britain through major healthcare providers including Bupa, Spire Healthcare, and Well Life Clinics, with new locations being onboarded weekly. The test utilises a simple saliva sample that can be collected at home, providing an end-to-end solution for genetic risk assessment.
The polygenic risk scores are largely uncorrelated with family history and traditional clinical risk factors, meaning most patients and their doctors would otherwise have no indication of elevated genetic disease risk. Unlike single-gene tests, the PRS approach combines information from millions of genetic variants to provide comprehensive risk assessment.
Technology and clinical utility
The test only needs to be taken once in a patient’s lifetime, allowing healthcare professionals to understand and act on disease risks years before symptoms develop. Healthcare providers receive integrated risk scores that combine genetic components with relevant clinical risk factors, enabling more informed clinical decision-making.
“Spire Healthcare is delighted to have signed an MoU with Genomics which enables our healthcare professionals to use predictive health insights, to deliver even more personalised advice and care to people,” said Justin Ash, CEO of Spire Healthcare.
Global expansion and market presence
Genomics’ Health Insights product is already available across the United States and is being offered by doctors in leading health systems. The company is in advanced discussions with partners in the Middle East, Asia, Australia, and the Caribbean as part of its global expansion strategy.
The company’s risk scores have been adopted by major biobanks including UK BioBank and Our Future Health. Genomics also collaborates with leading pharmaceutical companies including Vertex and Novo Nordisk on drug development programmes.
Company background and recognition
Founded in 2014 by world-leading geneticists from the University of Oxford, Genomics has been recognised in the 2025 Sunday Times 100Tech as one of Britain’s fastest-growing private tech companies. The company has raised over £100 million from investors including Foresite Capital, F-Prime, and IP Group.
Genomics operates from offices in Oxford, London, Cambridge, and Research Triangle Park in North Carolina, with laboratories in Framingham, Massachusetts.
- For more information, visit: https://www.genomics.com
